ðŸð± ç¬ç«ãã¥ãŒã¹ â 2026.04.17
ç¬8 ïŒ ç«5 ïŒ èš13ä»¶
ðŸ ç¬ãã¥ãŒã¹ â 2026.04.17
æ¬æ¥ 8ä»¶
1. ð¥ å»çã»çŸç ã»äºé²
ElancoãBefrenaïŒtirnovetmabïŒãç±³USDAæ£åŒæ¿èªââ6ã8é±ééã§æã€æ°èŠæIL-31ã¢ãã¯ããŒãã«æäœãäžåæçºå£²ãžæçµèª¿æŽ
ð 2025.12.31
Elanco Animal Healthã¯ãç¬ã®ã¢ã¬ã«ã®ãŒæ§ã»ã¢ãããŒæ§ç®èçãæšçãšããæ°èŠæIL-31ã¢ãã¯ããŒãã«æäœæ³šå°ãBefrenaïŒtirnovetmabïŒãã«ã€ããŠãç±³åœèŸ²åçïŒUSDAïŒããæ£åŒãªè£œé 販売æ¿èªãååŸãããæäžééã¯6ã8é±ãšåŸæ¥è£œå€ããé·ããå€å Žã®ã¢ã¬ã«ã®ãŒããŒã¯æã«ãéé¢è² æ ãæããããèšèšã«ãªã£ãŠãããäŒç€Ÿã¯ã2026幎äžåæã®ç±³åœåžå Žæå ¥ããæ¹ããŠç¢ºèªããŠããããã£ãŒã©ãŒã»åç©ç é¢ãžã®é éæºåãé²ããŠããã
ããã«ããæ¢åIL-31æäœãšæ¯ã¹ãé·ãè¬å¹æç¶ãšå¹Žéœ¢å¶éã®ãªãé©å¿ã§éžæè¢ãåºãããElancoã®æ¢ådermatology補åãZenreliaïŒilunocitinibïŒããšçµã¿åãããã°ãæ¥æ§æªåã®ã³ã³ãããŒã«ãšé·æå¯è§£ç¶æã䜿ãåãããããæ¥æ¬ã§ã¯æªæ¿èªã ããèŒžå ¥å人䜿çšã®çžè«ãå¢ããå¯èœæ§ããããç£å»åž«ã¯å¯Ÿå¿ãããŒãæŽããŠãããããç®èçãæ±ããç¬ã®é£Œãäž»ã¯ãã¹ããã€ããJAKé»å®³è¬ãæžããææ®µãšããŠãããã€ãå»ã«éžæè¢ãšããŠæç€ºããŠãããšè¯ãã
ð https://www.elanco.com/us/newsroom/press-releases/befrena-usda-approval
ð·ïž å»çã»çŸç ã»äºé²
2. 𧬠ç ç©¶ã»ç§åŠ
ãŽãŒã«ãã³ã»ã¬ããªãŒããŒã®è¥æºé¢é£éºäŒåââPTPN1ãšROMO1ãäœéå¢å ãšé¢é£ãPNASè«æã§åå®
ð 2026.03
ç±³åœã»è±åœã®å€æœèšããŒã ããè¥æºãªã¹ã¯ãé«ããŽãŒã«ãã³ã»ã¬ããªãŒããŒçŽ240é ã察象ã«ã²ãã ã¯ã€ãé¢é£è§£æïŒGWASïŒã宿œããäœéã»äœèèªçã»é£æ¬²è¡åãšé¢é£ããè€æ°ã®éºäŒåé åãç¹å®ããææã Proceedings of the National Academy of SciencesïŒPNASïŒã«æ²èŒããããšãã«PTPN1ïŒã€ã³ã¹ãªã³ã·ã°ãã«äŒéã®è² ã®å¶åŸ¡å åïŒãšROMO1ïŒããã³ã³ããªã¢æŽ»æ§é žçŽ ç£çé¢é£ïŒä»è¿ã®å€ç°ããè¥æºè¡šçŸåãšåŒ·ãé¢é£ããŠããã
ç¬ã®è¥æºã¯é¢ç¯çŸæ£ã»ç³å°¿ç ã»å¯¿åœççž®ã®ãªã¹ã¯å åãšããŠé·å¹Žç¥ãããŠããããããªãåãç°å¢ã§å€ªãç¬ãšããã§ãªãç¬ãããããã®ååçåºç€ãèŠããŠãããPTPN1ã¯ãã2åç³å°¿ç æ²»çã¿ãŒã²ããã§ããããç¬ã§ãè¬å€ä»å ¥ã®å¯èœæ§ãè°è«ããããã ãå®å°ã®é£Œãäž»ã«ãšã£ãŠã®æèšã¯åçŽã§ãã倪ããããè¡çµ±ãã®ç¬ã§ã¯é£äºå¶éã»éåèšèšãè¥éœ¢ãã峿 Œã«è¡ãããšã®éèŠæ§ããšããã³ã¹ã§è£ä»ããããããšããããšã«ãªãã
3. ð¥ å»çã»çŸç ã»äºé²
Ankyra TherapeuticsãcANK-101ãââIL-12åºå®åç²åã«ããç¬ã®æªæ§é»è²è «æ²»çã第I/IIçžã§å®¢èгçå¥å¹çãšå®å šæ§ããŒã¿ãå ¬è¡š
ð 2026.04
Ankyra Therapeuticsã¯ãã¢ã«ãããŠã æ°Žé žåç©ç²åã«IL-12ãåºå®åããŠè «çå æäžããæ°èŠå ç«çæ³ãcANK-101ãã®ãç¬ã®æªæ§é»è²è «ã«å¯Ÿãã第I/IIçžè©ŠéšããŒã¿ãç±³åœç£å»è «çåŠäŒã§çºè¡šãããè «çåšèŸºã«é«æ¿åºŠã®IL-12ãä¿æããŠå šèº«æ¯æ§ãæå°åããèšèšã§ãååãè€æ°åæäžã§è «ççž®å°ã»çåæéå»¶é·ã確èªãããéç¯€ãªæå®³äºè±¡ã¯éå®çã ã£ãã
ç¬ã®å£è å ã¡ã©ããŒãã¯è»¢ç§»æ§ãé«ãäºåŸäžè¯ã§ãçŸè¡ã®ããçšxenogeneic DNAã¯ã¯ãã³ãOnceptãã ãã§ã¯æ²»çæçžŸãé æã¡ã ã£ããcANK-101ã¯ç¬èªèº«ã®å ç«å¿çãè «ç屿ã§å¢å¹ ããæ°ããåçã§ãããé²è¡ãããšäœµèµ°ããéçºãã€ãã©ã€ã³ã§ããããåœå ã§ã¯æªå±éã ããé»è²ã¡ã©ããŒããšèšºæãããæç¬ã®é£Œãäž»ã¯ãæµ·å€èšåºè©Šéšæ å ±ã倧åŠç é¢ã§ã®æ²»éšåå æ©äŒã«ã€ããŠç£å»è «çç§ã«çžè«ãã䟡å€ãããã
ð https://www.ankyratx.com/
ð·ïž å»çã»çŸç ã»äºé²
4. ð æ é€ã»é£äº
IFFãç¬åãçµå£ãããã€ãªãã£ã¯ã¹ãPureStrong L. reuteriããæ¬§å·ã§å±ééå§ââè žç®¡ããªã¢ã»äŸ¿æ§ç¶æ¹åã蚎æ±
ð 2026.04.02
International Flavors & FragrancesïŒIFFïŒã®å¥åº·éšéã¯ãç¬åãçµå£ãããã€ãªãã£ã¯ã¹çŽ æãPureStrong Lactobacillus reuteriããæ¬§å·ã®ãããããŒãã»ãµããªã¡ã³ãã¡ãŒã«ãŒåãã«åæ¥å±ééå§ãããç¹èš±ä¿æã®L. reuterièæ ªããåžžæž©æµéã«èããåçµä¹Ÿç¥é¡ç²ãšããŠæäŸããããªãŒãã»ãã¬ãŒã¯ã»ã«ãã»ã«ãªã©å€æ§ãªè£œå€ãžé åã§ããç¹ãç¹åŸŽã ã
è žå 现èå¢ã®ä¹±ãã¯ãäžç¢ã»è»äŸ¿ã»ç®èãã©ãã«ã»è¡åç°åžžãšãé¢é£ãææãããŠãããããã§L. reuteriã¯äŸ¿ç§ã»éææ§è žçå矀ã«å¯Ÿããèšåºãšããã³ã¹ããããç¬ã§ãè»äŸ¿ã³ã³ãããŒã«ãšå ç«èª¿ç¯ã«é¢ããããŒã¿ãèç©ããã€ã€ããã飌ãäž»ã®å®åäžã¯ãããã°ããŒããããã€ã®åææè¡šèšã§ãLactobacillus reuteriããåçã®ãããã€ãªãã£ã¯ã¹çš®ã確èªããããšãšãç£å»åž«ãšãé·ææäžã®å¿ èŠæ§ãšäŒè¬ã¿ã€ãã³ã°ããçžè«ããããšãéµãšãªãã
ð https://www.iff.com/
5. 𧬠ç ç©¶ã»ç§åŠ
Cornell倧åŠã飌ãäž»ã»ããªãŒããŒã»ç£å»åž«åããç¬ã²ãã å»åŠããªã³ã©ã€ã³è¬åº§ã4/14éè¬ââéºäŒåæ€æ»ã®çµæãèšåºå€æã«ã©ãèœãšãã
ð 2026.04.14
ã³ãŒãã«å€§åŠç£å»åŠéšã¯ãç¬ã®ã²ãã å»åŠïŒcanine genomic medicineïŒãããŒãã«ãããªã³ã©ã€ã³çæè¬åº§ã4æ14æ¥ã«éè¬ããã察象ã¯ããªãŒããŒãç£å»åž«ã飌è²ç®¡çè ãç ç©¶è ã§ãæ¶è²»è åãéºäŒåæ€æ»ã®è§£éãéºäŒæ§çŸæ£ããŒã«ãŒã®åŠ¥åœæ§è©äŸ¡ãå€éºäŒåãªã¹ã¯ã¹ã³ã¢ãããªãŒãã£ã³ã°ããã°ã©ã ãžã®å¿çšãªã©ãäœç³»çã«åŠã¹ãæ§æãè¬åž«é£ã«ã¯Adam Boykoå士ãRory Todhunterå士ãå倧ã®ç¬¬äžç·ç ç©¶è ã䞊ã¶ã
éºäŒåæ€æ»ã¯ãã§ã«å®¶åºã§ç°¡åã«ã§ããæä»£ã ãããçµæãã©ãèªãã§ãã©ã飌è²ã»æ²»çã«åæ ããããã®ãªãã©ã·ãŒã¯è¿œãã€ããŠããªãã誀解ã«åºã¥ãç¹æ®é€å€ãæ²»ç倿ã¯ãç¬ã®çŠç¥ã«ã圱é¿ãããããªãŒããŒã»ä¿è·å£äœã»ç£å»åž«ã¯æ¬è¬åº§ã®ãããªå ¬åŒæè²ããã°ã©ã ãåè¬ããããšã§ã飌ãäž»ãžã®èª¬æè²¬ä»»ãæããããããªããå人ã®é£Œãäž»ã«ãšã£ãŠãããæ€æ»ãåããååŸã«ç£å»åž«ãšäœãçžè«ãã¹ãããã®èãæ¹ãæŽçã§ããè¯ãæ©äŒã ã
ð https://www.vet.cornell.edu/
6. ð§ ãã¬ãŒãã³ã°ã»è¡åç§åŠ
Poodleããã¯ã¹ç¬ïŒã©ãã©ãã¥ãŒãã«ã»ã³ãã«ããŒã»ãã£ãããŒïŒã®åé¡è¡åãçŽè¡çš®ãããããå ããã»åé¢äžå®åŒ·ããåŸåââPLOS ONE 3/19å ¬è¡š
ð 2026.03.19
PLOS ONEã«3æ19æ¥å ¬éãããæšªæç ç©¶ã¯ã人æ°ã®é«ãPoodleããã¯ã¹ç¬3ç¬çš®ïŒCockapooãLabradoodleãCavapooïŒãããã®èŠªç¬çš®4çš®ïŒã³ãã«ãŒã¹ãããšã«ãã©ãã©ããŒã«ããã£ããªã¢ãã³ã°ãã£ãŒã«ãºã¹ãããšã«ãããŒãã«ïŒãšC-BARQïŒç¬è¡å質å祚ïŒã¹ã³ã¢ã§æ¯èŒãããããã¶ã€ããŒããã°ã¯çŽè¡çš®ãããæ±ããããããšããå··éã®èšèª¬ãã3,691é ã®ããŒã¿ã§æ€èšŒãã圢ã ã
çµæã¯ãããã¯ã¹ç¬ã¯å ãã»åé¢äžå®ã»èŠç¥ãã¬äººãžã®ææã»è奮æ§ãªã©ã§çŽè¡çš®ããé«ã¹ã³ã¢ïŒããåé¡è¡åãç®ç«ã€ïŒã瀺ããããã¶ã€ããŒïŒé£ŒããããããšããããŒã±ãã£ã³ã°ç䞻匵ã«ã¯ç矩ãããããšã瀺ããããããããç¬ãè¿ããå®¶åºã«ãšã£ãŠã¯ãèŠãç®ã®å¯æããã¢ã¬ã«ã²ã³äœæžã謳ãåºåãããã䞡芪ç¬ã®æ§æ Œã»ç³»çµ±ã»ç¹æ®ç°å¢ã»ç€ŸäŒåç¶æ³ãéèŠãã倿ææãšãªãããã¬ãŒããŒã»ç£å»è¡ååŠã®å°éå®¶ããããã¯ã¹ç¬ã®é£Œãäž»åãæ¯æŽäœå¶ãæŽããå¿ èŠæ§ãé«ãŸã£ãŠããã
ð https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0342847
ð·ïž ãã¬ãŒãã³ã°ã»è¡åç§åŠ
7. ð ç¬åŠ
Scientific Reportsæ²èŒEEGç ç©¶ââç¬ãæ«ã§ãŠã¢ã€ã³ã³ã¿ã¯ããåããšãã¬ãããã¿ããè³ã®Î²ã»Î³åž¯å掻åã匷ãåå¿
ð 2026.04
Scientific Reportsèªã«æ²èŒãããææ°EEGç ç©¶ã¯ããããå®ç©ã®ç¬ãæ«ã§ãã»ã¢ã€ã³ã³ã¿ã¯ããåãå Žé¢ãšãåãµã€ãºã®ã¬ãããã¿ã§åãè¡çºãè¡ãå Žé¢ã§ãè³ã®é»æ°æŽ»åããªã¢ã«ã¿ã€ã æ¯èŒãããåå è ã¯èš40åè¶ ã§ãé ç®äžã®è€æ°é»æ¥µããèšé²ãããè³æ³¢ã¯ãç¬ãšçžäºäœçšããæ¡ä»¶ã§ç¹ã«Î²ã»Î³åž¯åã®ãã¯ãŒãææã«å¢å ããã
βã»Î³åž¯åã¯æ³šæã»æ åå¶åŸ¡ã»ç€ŸäŒçèªç¥ã«é¢ãããšãããããã®çµæã¯ãç¬ãšè§Šãåãããšã«ãããªã©ã¯ãŒãŒã·ã§ã³å¹æããåãªãæ«ã§ãåäœãã§ã¯ãªããçžäºäœçšãã®ãã®ãã«ãã£ãŠçããããšã瀺åãããã¢ããã«ã»ã©ããŒãé«éœ¢è æœèšã»æè²çŸå Žã§ã®ç¬ä»åšããã°ã©ã ã®ãšããã³ã¹ãäžã€ç©ã¿äžãã£ãããšã«ãªããå®¶åºã§ãã1æ¥æ°åã§ãæç¬ãšç®ãåãããŠéãã«æ«ã§ãæéãæã€ããšãã飌ãäž»ã®ã¹ãã¬ã¹äœæžã«ã€ãªããããã
ð https://www.nature.com/articles/s41598-026-45639-2
8. ð¥ å»çã»çŸç ã»äºé²
Trupanion 2026幎Q1ããŒã¿ââç¬ã®ããªãã¡ãäžæ¯ã«ããä¿éºè«æ±ãåå¹Žåææ¯22%å¢ãå·å¥ã§å·æ³ç·©åãšçžé¢
ð 2026.04
ãããä¿éºå€§æTrupanionãçºè¡šãã2026幎第1ååæã®ã¯ã¬ãŒã ãã¬ã³ãã§ãç¬ã®ããªãã¡ãïŒTHCïŒäžæ¯ã«ããåç©ç é¢å蚺ä¿éºè«æ±ãåå¹Žåææ¯22%å¢å ããããšãæããã«ãªã£ãããšãã«2024ã2025幎ã«å奜çšå€§éº»ã®åæ³åãé²ãã å·ã§ã€ã³ã·ãã³ããé¡èã«å¢ããŠãããå®¶åºå ã§ã®ãšãã£ãã«ïŒé£çšå€§éº»ïŒèª€é£ãäž»å ãšã¿ãããã
çç¶ã¯åç ãéå倱調ã尿倱çŠãäœæž©äœäžãåŸèãªã©ããšãã£ãã«ã¯é«æ¿åºŠãã€ãã§ã³ã¬ãŒãããã¿ãŒå ¥ã補åãå€ããç¬ã«ãšã£ãŠã¯è€åãªã¹ã¯ãšãªãã飌ãäž»ããæ¥ãããããŠç£å»ã«èšããªããã±ãŒã¹ãããããæ©æã®èšºæãšæ¯æçæ³ïŒèŒžæ¶²ã»æŽ»æ§çã»äœæž©ç®¡çïŒã§äºåŸã¯æ¯èŒçè¯å¥œãªã®ã§ãççŽãªæ å ±æäŸãäœããéèŠã ãæ¥æ¬ã§ã¯å奜çšå€§éº»ã¯éåæ³ã ããCBDãå«ããããçšè£œåãæµ·å€åž°åœå®¶åºã§è£œåãæ··å ¥ããã±ãŒã¹ããããæ²¹æã¯çŠç©ã
æ°è¬æ¿èªãéºäŒåæ€æ»ã®æ®åãããã¯ã¹ç¬ã®è¡åããŒã¿ãEEGç ç©¶ââ2026幎æ¥ã¯ãç¬ãšã®æ®ãããç§åŠã§åå®çŸ©ããããã¥ãŒã¹ãç¶ããŠãããæç¬ã®å¥åº·ç®¡çããæ ¹æ ã«åºã¥ããŠéžã¶æä»£ãžã
ð·ïž å»çã»çŸç ã»äºé²
ð¡ 仿¥ã®ã¯ã³ãã€ã³ãïŒç¬ïŒ
æ°è¬æ¿èªãéºäŒåæ€æ»ã®æ®åãããã¯ã¹ç¬ã®è¡åããŒã¿ãEEGç ç©¶ââ2026幎æ¥ã¯ãç¬ãšã®æ®ãããç§åŠã§åå®çŸ©ããããã¥ãŒã¹ãç¶ããŠãããæç¬ã®å¥åº·ç®¡çããæ ¹æ ã«åºã¥ããŠéžã¶æä»£ãžã
ð± ãã³ãã¥ãŒã¹ â 2026.04.17
æ¬æ¥ 5ä»¶
9. ð¥ å»çã»çŸç ã»äºé²
Gallantã®ãç«ã®å€åœ¢æ§é¢ç¯çã«å¯ŸããUMSCéæ³šå¹¹çްèçæ³ãââãã€ããã詊éšã§è¯å¥œãªé®çã»å¯ååæ¹åãFDAæ¡åŒµæ¡ä»¶æ¿èªãã¹ãŠã§ã€é©æ Œæ§ãç²åŸ
ð 2026.04
Gallantã¯ãç«ã®èªç¶çºçåå€åœ¢æ§é¢ç¯çïŒOAïŒã«å¯Ÿããåå®®ç±æ¥éèç³»é質现èïŒUMSCïŒã®éèå æäžçæ³ã«ã€ããŠããã€ãããèšåºè©Šéšã®è¯å¥œãªããŒã¿ãçºè¡šãããçŒçã¹ã³ã¢ã»æŽ»åéïŒé£Œãäž»è©äŸ¡ããã³æŽ»åèšããŒã¿ïŒã»é¢ç¯å¯ååã®è€æ°ææšã§æ¹åã確èªãããç®ç«ã£ãæå®³äºè±¡ã¯ãªãã£ããåæã«FDAåç©çšå»è¬åã»ã³ã¿ãŒïŒCVMïŒãããæ¡åŒµæ¡ä»¶æ¿èªïŒexpanded conditional approvalïŒãã¹ãŠã§ã€ã®é©æ Œæ§èªå®ãååŸããŠããã
OAã¯é«éœ¢ç«ã®çŽ90%ã«æœåšãããšãããããç«ã¯çã¿ãé ãç¿æ§ãããçç¶ãéå°è©äŸ¡ãããã¡ã ãæ¢åã®ã°ã©ã³ãœã«ãã«ïŒéªšé¢ç¯ççšæNGFã¢ãã¯ããŒãã«æäœïŒã«ç¶ããéæ³šåã®å¹¹çްè補åãéžæè¢ã«å ããã°ãé¢ç¯ãçŽæ¥æ³šå°ã§ããªãç«ã§ãå šèº«ã¢ãããŒããå¯èœã«ãªããGallantã¯æ¢ã«å£è çïŒFCGSïŒåã幹现èçæ³ã®æ¡ä»¶ä»ãæ¿èªã幎å èŠèŸŒã¿ã§ãç«ã®åçå»çã¯äžæ°ã«å®è£ ãã§ãŒãºã«å ¥ãã飌ãäž»ã¯ãæç«ã®ãæè¿ãžã£ã³ãããªããªã£ãããã°ã«ãŒãã³ã°ãéã«ãªã£ãããªã©ã®å åã«ææã§ãã£ãŠã»ããã
ð·ïž å»çã»çŸç ã»äºé²
10. 𧬠ç ç©¶ã»ç§åŠ
Toxoplasma gondiiãåŸæŸæãã©ãã£ãŸã€ããã®äºåã3ã€ã«ååé¡ââNature Communicationsã1/15ä»ãªã³ã©ã€ã³æ²èŒ
ð 2026.01.15
Nature Communicationsèªã«ãç«ã®å¯çåè« Toxoplasma gondii ã®æ ¢æ§ææçžïŒãã©ãã£ãŸã€ã段éïŒã«ã€ããŠãåŸæ¥1çš®ãšèããããŠããã·ã¹ããåäžçްèè§£æã§3ã€ã®æ©èœçäºåã«åé¡ã§ããããšã瀺ããè«æãæ²èŒããããäºåããšã«ä»£è¬ãããã¡ã€ã«ã»å®¿äž»å¿çãžã®åœ±é¿ã»å掻æ§åãªã¹ã¯ãç°ãªãããšã瀺åãããåæŽ»æ§åãæããè¬å€èšèšã«æ°ããèŠç¹ãäžããææã ã
ãããœãã©ãºãã¯ç«ãçµå®¿äž»ãšããããããåŠåš äžææã»å ç«æå¶æ£è ã§ã®å掻æ§åãªã©å ¬è¡è¡çäžãéèŠã ãç«ã¯å€é£Œãã»çèæåã»éçåç©æç²ã§ææããããã飌ãäž»ã¯â å®å šå®€å 飌è²ã培åºãâ¡åŠåé£ã§ã¯ãªãç±åŠçé£ãäžãããâ¢ç å Žããã€ã¬æž ææã¯æè¢ççšããªã©ã®äºé²ãèŠããŠãããããåŠåš äžã®é£Œãäž»ã¯ãç«ã®ãã€ã¬æé€ãå®¶æã«ä»»ãããšå®å šãç 究段éã®ç¥èŠã§ã¯ãããããç«âããããªã¹ã¯ã®çè§£ãæ·±ãŸãæçŸ©ã¯å€§ããã
ð https://www.nature.com/ncomms/
11. 𧬠ç ç©¶ã»ç§åŠ
Calgary倧åŠãšColorado Stateãç«H5N1é«ç åæ§é³¥ã€ã³ãã«ãšã³ã¶ã¯ã¯ãã³ç¬¬Içžèšåºè©Šéšâânpj Vaccines 1æå·ã§å®å šæ§ãšå ç«åæ§ã確èª
ð 2026.01
npj Vaccinesèª1æå·ã«ãç«ã®é«ç åæ§é³¥ã€ã³ãã«ãšã³ã¶ïŒH5N1ïŒã¯ã¯ãã³ã®ç¬¬Içžèšåºè©Šéšçµæãæ²èŒããããã«ããã»ã«ã«ã¬ãªãŒå€§åŠãšç±³ã³ãã©ãå·ç«å€§åŠã®å ±åç ç©¶ã§ãäžæŽ»åH5N1æåãšã¢ãžã¥ãã³ããçµã¿åãããç®äžæ¥çš®ã¯ã¯ãã³ãå¥åžžæç«çŸ€ã«æäžããå®å šæ§ãšæ¶²æ§å ç«ïŒäžåæäœäŸ¡ïŒå¿çãè©äŸ¡ãããéç¯€ãªæå®³äºè±¡ã¯å ±åãããã2åæ¥çš®ã§ååãªäžåæäœäŸ¡ã®èªå°ã確èªããã
ç±³åœã§ã¯2024幎以éãä¹³çã§ã®H5N1æµè¡ã«äŒŽãç«ãžã®æ³¢åææäŸãçžæ¬¡ããçä¹³ã»ææé¶èæåãå±å€æŽé²ãä»ããèŽæ»äŸãå®¶åºç«ã§ãå ±åãããŠããããããžã®ã¹ãã«ãªãŒããŒãªã¹ã¯ãèŠæããããªããç«çšã¯ã¯ãã³ã¯ã¯ã³ãã«ã¹ïŒOne HealthïŒæŠç¥ãšããŠéèŠã ãåœå æ¿èªã«ã¯ãŸã æéãå¿ èŠã ããç£å»åž«äŒãé€é¶æ¥çã§ã¯ä»åŸã®ååãæ³šèŠãããã飌ãäž»ã«ã§ããæå€§ã®å¯Ÿçã¯ãå®å šå®€å 飌è²ããšãæªå ç±ä¹³ã»çèãäžããªããããšã«å°œããã
ð https://www.nature.com/npjvaccines/
12. ð§ ãã¬ãŒãã³ã°ã»è¡åç§åŠ
Purina Instituteãç«ã®åé¢é¢é£è¡åé害ïŒfeline separation-related disorderïŒãã®åœéå°éå®¶ã³ã³ã»ã³ãµã¹ãå ¬è¡šââãã€æ§ã»æ»ææ§ã»ç Žå£è¡åã®èå¥ã¬ã€ã
ð 2026.04
Purina Instituteã¯ãç£å»è¡ååŠã®åœéå°éå®¶ããã«ã«ãããç«ã®åé¢é¢é£è¡åé害ïŒfeline separation-related disorder: FSRDïŒãã®ã³ã³ã»ã³ãµã¹ã¹ããŒãã¡ã³ããçºè¡šãããåŸæ¥ã¯ãç«ã¯ç¬ç«å¿ã匷ãåé¢äžå®ã«ãªããªãããšãããã¡ã ã£ãããå®éã«ã¯é£Œãäž»äžåšæã«éå°ã°ã«ãŒãã³ã°ãäžé©åææ³ãç Žå£è¡åã飿¬²äœäžãçºå£°å¢å ãªã©ãåããç«ãäžå®å²åååšããããšãå確èªãã蚺æãã§ãã¯ãªã¹ãã»éå¥èšºæã»ä»å ¥ã®åªå é äœã瀺ããŠããã
å ·äœçãªé£Œãäž»åãã¢ããã€ã¹ãšããŠãåºçºåã®ãéããªååŒåããäžåšæã®ç°å¢ãšã³ãªããã¡ã³ãïŒããŒãããºã«ã»çªèŸºã®äŒæ¯å ŽæïŒãã«ã¡ã©è¶ãã®è¡åèšé²ãå¿ èŠãªãå°éå®¶æå°äžã§ã®ãã©ã¯ãŒãšãã»ã³ã¹ãæäžå®è¬ã®æ€èšãªã©ãæããããããç«ã ããå¹³æ°ããšããå å ¥èŠ³ãæšãŠãçå®çªäžã®è¡åå€åã«ç®ãåããããšããæç«ã®QOLãšé£Œãäž»ãšã®çµãå®ãç¬¬äžæ©ã«ãªãã
ð https://www.purinainstitute.com/
ð·ïž ãã¬ãŒãã³ã°ã»è¡åç§åŠ
13. ð§ ãã¬ãŒãã³ã°ã»è¡åç§åŠ
ãã©ã³ã¹ã»ãªãšã³å€§åŠããç«ã¯ã©ã話ãããããããããã630人ã®é£Œãäž»ããŒã¿ããè§£æââé«ã声ã»çããã¬ãŒãºã»åååŒã³ã§ææã«åå¿å¢å
ð 2026.04
ãã©ã³ã¹ã»ãªãšã³å€§åŠã®åç©è¡ååŠããŒã ã¯ã630åã®ç«é£Œãäž»ããéããæ¥åžžã®å¯Ÿè©±ããŒã¿ãè§£æããç«ãã©ããªè©±ãããæ¹ã«æãåå¿ããããå ±åãããé«ã声ã®ããŒã³ïŒãããã”pet-directed speech”ïŒãçãåçŽãªãã¬ãŒãºãé »ç¹ã«ååãåŒã¶ãã®3èŠçŽ ãæããšãç«ã飌ãäž»ã®åŒã³ããã«æ¯ãåãã»è¿ã¥ãã»å°»å°Ÿãç«ãŠãçã®è¯å®çåå¿ã瀺ã確çãææã«é«ãã£ãã
ç¬ã§ã®ã幌å èªé¢šçºè©±ïŒdog-directed speechïŒãç ç©¶ã¯èç©ãå€ãããç«ã«ã€ããŠã®å€§èŠæš¡ããŒã¿ã¯éãããŠãããä»åã®ææã¯ãç«ã飌ãäž»ããã®çºè©±æ§åŒãåŒå¥ããŠå¿çããããšãè£ä»ãã飌ãäž»ãšç«ã®æ åççµã匷åããå®è·µçãã³ããäžããã詊ã䟡å€ãããã®ã¯ãæ¯æ¥æ±ºãŸã£ãæéã«ãé«ã声ã§çãååãåŒãã§è©±ãããããã«ãŒãã£ã³ãç¹ã«å€é 飌ãã§ã¯åã ã®ååãæèçã«äœ¿ãããšã§ãç«ã®ã¹ãã¬ã¹ãšå®¶æå ã®é¢ä¿æ§æ¹åã«ã€ãªããã
ç«ããç§åŠã®å¯Ÿè±¡ããšããŠç ç©¶ãæ¥éã«é²ãã§ããã幹现èçæ³ãã¯ã¯ãã³ãåé¢é¢é£é害ãçºè©±åå¿ããç«ã ãã仿¹ãªããã§çä»ããããŠããå€ãã®ããšã«ãæ ¹æ ã«åºã¥ãæç«ãŠãèŠããŠããã
ð https://www.univ-lyon1.fr/
ð·ïž ãã¬ãŒãã³ã°ã»è¡åç§åŠ
ð¡ 仿¥ã®ã¯ã³ãã€ã³ãïŒç«ïŒ
ç«ããç§åŠã®å¯Ÿè±¡ããšããŠç ç©¶ãæ¥éã«é²ãã§ããã幹现èçæ³ãã¯ã¯ãã³ãåé¢é¢é£é害ãçºè©±åå¿ããç«ã ãã仿¹ãªããã§çä»ããããŠããå€ãã®ããšã«ãæ ¹æ ã«åºã¥ãæç«ãŠãèŠããŠããã
æ¯æ7æé ä¿¡

ã³ã¡ã³ããæ®ã